文献速递妇科肿瘤

HPV疫苗接种时代中低收入国家宫颈癌放疗扩容的需求与经济影响模型分析

Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.
PubMed 文献 · Lancet Oncol · 2019-05-28

该模型研究基于全球放疗投资框架,评估2015–2035年中低收入国家宫颈癌外照射和近距离放疗扩容的健康与经济收益,并模拟HPV疫苗接种(75%覆盖率)至2072年的影响。即使接种疫苗,放疗扩容仍必要且回报显著。

核心结论

  • 有效宫颈癌控制需综合策略,即使有HPV疫苗接种,放疗扩容仍必不可少且带来巨大健康收益和强投资回报。

研究设计与样本

  • 应用全球放疗控制工作组投资框架,模拟2015–2035年中高、中低、低收入国家宫颈癌外照射和近距离放疗扩容的健康经济收益。
  • 模型估算外照射和近距离放疗独特成本,并纳入女性照护贡献估值,同时模拟HPV疫苗接种(75%覆盖率)至2072年。

临床怎么用

  • 在中低收入国家,宫颈癌治疗规划应同步推进放疗扩容与HPV疫苗接种,不可因疫苗覆盖而削减放疗投资。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy is standard of care for cervical cancer, but major global gaps in access exist, particularly in low-income and middle-income countries. We modelled the health and economic benefits of a 20-year radiotherapy scale-up to estimate the long-term demand for treatment in the context of human papillomavirus (HPV) vaccination. METHODS: We applied the Global Task Force on Radiotherapy for Cancer Control investment framework to model the health and economic benefits of scaling up external-beam radiotherapy and brachytherapy for cervical cancer in upper-middle-income, lower-middle-income, and low-income countries between 2015 and 2035. We estimated the unique costs of external-beam radiotherapy and brachytherapy and included a specific valuation of women's caregiving contributions. Model outcomes life-years gained and the human capital and full income net present value of investment. We estimated the effects of stage at diagnosis, radiotherapy delivery system, and simultaneous HPV vaccination (75% coverage) up to a time horizon set at 2072. FINDINGS: For the period from 2015 to 2035, we estimated that 9·4 million women in low-income and middle-income countries required treatment with external-beam radiotherapy, of which 7·0 million also required treatment with brachytherapy. Incremental scale-up of radiotherapy in these countries from 2015 to meet optimal radiotherapy demand by 2035 yielded 11·4 million life-years gained, $59·3 billion in human capital net present value (-$1·5 billion in low-income, $19·9 billion in lower-middle-income, and $40·9 billion in upper-middle-income countries), and $151·5 billion in full income net present value ($1·5 billion in low-income countries, $53·6 billion in lower-middle-income countries, and $96·4 billion in upper-middle-income countries). Benefits increased with advanced stage of cervical cancer and more efficient scale up of radiotherapy. Bivalent HPV vaccination of 12-year-old girls resulted in a 3·9% reduction in incident cases from 2015-2035. By 2072, when the first vaccinated cohort of girls reaches 70 years of age, vaccination yielded a 22·9% reduction in cervical cancer incidence, with 38·4 million requiring external-beam radiotherapy and 28·8 million requiring brachytherapy. INTERPRETATION: Effective cervical cancer control requires a comprehensive strategy. Even with HPV vaccination, radiotherapy treatment scale-up remains essential and produces large health benefits and a strong return on investment to countries at different levels of development. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rodin D, Burger EA, Atun R, et al. Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. Lancet Oncol. 2019. PMID: 31151906. doi:10.1016/S1470-2045(19)30308-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。